key: cord-0909329-u3jwmsy5 authors: Dotolo, Serena; Marabotti, Anna; Facchiano, Angelo; Tagliaferri, Roberto title: A review on drug repurposing applicable to COVID-19 date: 2020-11-05 journal: Brief Bioinform DOI: 10.1093/bib/bbaa288 sha: a1442dbc5267764aa4a59104efc80a257414fa7a doc_id: 909329 cord_uid: u3jwmsy5 Drug repurposing involves the identification of new applications for existing drugs at a lower cost and in a shorter time. There are different computational drug-repurposing strategies and some of these approaches have been applied to the coronavirus disease 2019 (COVID-19) pandemic. Computational drug-repositioning approaches applied to COVID-19 can be broadly categorized into (i) network-based models, (ii) structure-based approaches and (iii) artificial intelligence (AI) approaches. Network-based approaches are divided into two categories: network-based clustering approaches and network-based propagation approaches. Both of them allowed to annotate some important patterns, to identify proteins that are functionally associated with COVID-19 and to discover novel drug–disease or drug–target relationships useful for new therapies. Structure-based approaches allowed to identify small chemical compounds able to bind macromolecular targets to evaluate how a chemical compound can interact with the biological counterpart, trying to find new applications for existing drugs. AI-based networks appear, at the moment, less relevant since they need more data for their application. Recycling old drugs trying to treat new diseases, rescuing shelved drugs and extending patents' lives make drug repurposing (also known as drug repositioning) an attractive form of drug discovery [1] [2] [3] [4] . Repurposing can help to identify new therapies for diseases at a lower cost and in a shorter time, particularly in those cases where preclinical safety studies have already been completed [5] . It can play a key role in "therapeutic stratification procedure" for patients with rare, complex or chronic diseases with less effective or no marketed treatment options available [6] . To date, the most notable repurposed drugs have been discovered either through serendipity, based on specific pharmacological insights or using experimental screening platforms [7] [8] [9] [10] [11] . The advent of genomics technologies and computational approaches has led to the development of novel approaches Dr. Serena Dotolo is a post-doctoral researcher in the group of Prof. Roberto Tagliaferri at the University of Salerno. She is actively involved in the study of protein-protein networks by means of bioinformatics to identify new molecular targets for the development of innovative diagnostic and therapeutic approaches of complex diseases. Prof. Anna Marabotti is an Associate Professor of the University of Salerno. Her main research focus is the analysis and prediction of structures and structure-function-dynamics relationships of proteins involved in rare diseases, and the development of new therapies using computational biology approaches. defined by available information and elucidated mechanisms, such as drug-oriented, disease-oriented and treatment-oriented [16] . These computational drug-repositioning methods enable researchers to examine nearly all drug candidates and test them on a relatively large number of diseases within significantly shortened time lines. Therefore, integration of translational bioinformatics resources can enable the rapid application of drug repositioning on an increasingly broader scale [17, 18] . Efficient tools are now available for systematic drug-repositioning methods using large repositories of compounds with biological activities [19, 20] . Drug-repurposing strategy has been applied to various epidemics diseases and finds its relevant role with the coronavirus disease 2019 (COVID-19) pandemic [21] . COVID-19 has emerged by a novel coronavirus, now known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [21] . The evidences on the mechanism of infection, also derived from previous studies on coronaviruses, suggest that a key process is the interaction of viral spike protein with human angiotensinconverting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2): the receptor-binding domain of spike protein binds to the peptidase domain of human ACE2. In this way, this last protein assumes the role of receptor in the binding of the virus to the host cell [23, 24] . The role of TMPRSS is related to the infection process, as it is one of the host proteases that cleave the spike protein in specific sites, thus activating the viral entrance in the host cell [23, 25, 26] . The main protease (Mpro) of SARS-CoV-2 is a key enzyme, which plays a pivotal role in mediating viral replication and transcription [27] . The other viral proteins concur in virus replication and spreading [28] . An in silico [29] and an experimental [30] analysis of the interaction network between human and SARS-CoV-2 proteins have been recently published and could suggest the most important targets for developing therapeutic approaches against this virus. Drug repurposing has already been suggested for specific drugs in the treatment of the current COVID-19 outbreak [31] . In particular, a remarkable number of drugs reconsidered for COVID-19 therapy are or have been used in cancer therapy [32] . Indeed, potentially suitable drugs against this virus are essentially those affecting signal transduction, synthesis of macromolecules and/or bioenergetics pathways and those able to interfere with the host immune response, in particular, the life-threatening cytokine storm associated with severe COVID-19. Additionally, antiviral compounds are occasionally effective in fighting cancer [33] . Here we will explain the most widely used computational drug-repurposing techniques applied to the search for new therapeutic approaches against COVID-19. Questa parte mi sembrava che fosse stata cancellata nella revised version! Non era così? The drug-repurposing workflow is organized differently from traditional drug development. In drug repurposing there are fewer steps and different parameters to follow: compound identification, compound acquisition, development and Food and Drug Administration (FDA) post-market safety monitoring. Computational drug-repositioning approaches applied on COVID-19 can be broadly categorized as (i) network-based models, (ii) structure-based approaches or (iii) machine/deep learning approaches [4, 18, 19] (Figure 1 ). There are some papers that used hybrid approaches, and we classify, for example, a method consisting of both network and clustering as networkbased if we think that network modeling is prevalent over machine learning. In this way, we find only few methods in which AI models are the prevalent methodology. Network-based approaches are vital and widely used in drug repositioning due to the associated ability to integrate multiple data sources [34, 35] . With the advances of highthroughput technology and bioinformatics methods, molecular interactions in the biological systems can be modeled by networks [36] . In these models, network nodes represent drugs, diseases or gene products, while edges represent interactions or relationships between nodes [37, 38] . The resulting pattern may facilitate the process of structure-guided pharmaceutical and diagnostic research with the prospect of identifying potential new biological targets. Previous studies have suggested that drug-target networks, drug-drug networks, drug-disease networks and protein interaction networks are useful in the identification of new opportunities for drug discovery or repositioning [39] . Network-based methodology combines a system pharmacology-based network medicine platform that quantifies the interplay between the virus-host interactome and drug targets in the human protein-protein interaction network [40] . There are two types of network-based approaches reviewed and applied to COVID-19 [41] : network-based clustering approaches and network-based propagation approaches. Network-based clustering approaches have been proposed to discover novel drug-disease or drug-target relationships [42] . These approaches aim to find several modules (drug-disease, drug-drug or drug-target) using clustering algorithms according to the topology structures of networks. Network-based propagation approaches are another important type of network-based approach. Human coronavirus (HCoV)-associated host proteins were collected from the literature and pooled to generate a pan-HCoV protein subnetwork. Network proximity between drug targets and HCoV-associated proteins was calculated to screen for candidate repurposable drugs for HCoVs under the human protein interactome model. By using a network-based method it is possible to analyze some important patterns useful to annotate the proteins that are functionally associated with HCoVs, which are localized within the comprehensive human interactome network. Furthermore, they can model the proteins that serve as drug targets for a specific disease and they may be suitable drug targets for potential antiviral infections owing to shared protein-protein interactions elucidated by the human interactome [43, 44] . The most important and relevant network-based approaches used for COVID-19 are summarized in Table 1 , which shows their benefits, bottlenecks, databases and other information. The 1st six approaches [45, 50] are based on clustering methodologies applied to protein-protein interactions (PPIs), drug-proteindisease, drug-target-disease and drug-disease, while the last two approaches [51, 52] are based on the propagation methodology. Both methodologies have been explained within the text. Moreover, these methodologies not only provide an opportunity to improve the performance of existing methods but also offer a tool to design more efficient and stable approaches. Virtual screening can help in identifying small chemical compounds able to bind macromolecular targets with known or predicted 3D structure. It allows to screen even millions of compounds in a limited time, reducing the costs for finding hits suitable to develop new drugs, as well as to find new targets for existing drugs. This approach is based mainly on molecular docking, a computational strategy first developed to understand how a chemical compound can interact with a biological counterpart, but nowadays largely used for many other tasks, including drug repurposing [53, 54] . The 1st examples of structure-based drug repurposing applied to COVID-19 were published even before 3D structures of the viral proteins became available. Researchers applied homology modeling methods [55] to predict the structures of several target viral proteins, such as 3-chymotrypsin-like (3CL) protease, also known as main protease (Mpro), Spike, RNAdependent RNA polymerase (RdRp), helicase and papain-like (PL) protease, which were identified as the most important targets for antiviral activity. These models were then used to perform virtual screening of compound libraries, including approved drugs for clinics and natural compounds. However, very soon after the isolation of the SARS-CoV-2 virion particle and genome sequencing, the structural biology community started an unprecedented huge effort to solve the structures of the most important proteins involved in viral infection, replication and dissemination. Protein Data Bank (PDB), the worldwide database for macromolecular structures [56] opened a section dedicated to COVID-19-related entries, and the 1st structure, deposited on 5 February 2020, was the one of SARS-CoV-2 Mpro in complex with an inhibitor identified by computer-aided drug design, solved at 2.16 Å resolution [27] (Supplementary Figure 1 ). Since then, almost 500 structures of SARS-CoV-2 proteins (update: 14 October 2020), alone or associated to ligands and/or to their target cell receptors, have been solved and made available to the scientific community. The structures have been solved mainly by X-ray crystallography (about 80% of structures) and with a good resolution (≤ 2.5 Å in about 67% of structures). The release of these data has triggered an explosion of computational studies aimed at predicting the ability of known drugs either to inhibit their activity, or to impair the recognition and association with cell counterparts, necessary for the virus to penetrate the host cells and replicate. The general protocol applied was the extensive virtual screening of databases of drugs, made by different docking approaches, often followed by further computational protocols, such as molecular dynamics simulations and the prediction of the free energy associated to the interaction of the top hits with the selected target protein, in an effort to increase the reliability of the docking results [57] . Generally, no experimental validation was provided to the results. The starting point for screening were usually very popular databases with at least a section dedicated to approved drugs, which can provide the molecular structures of the chemical com-pounds in a docking-ready format. Some examples of general, freely available databases are ZINC [58] , PubChem [59] , DrugBank [60] , Drug3D [61] , SuperDRUG2 [62] , ChEMBL [63] , KEGG [64] and MTiOpenScreen [65] . Also, Asinex (http://www.asine x.com/), KNApSAcK (http://www.knapsackfamily.com/KNApSA cK/), NPC (https://tripod.nih.gov/npc/), Reaxys (https://www.rea xys.com) and Selleckchem (https://www.selleckchem.com/) are popular resources for virtual screening of drugs, made by private companies. Other more focused databases for drug repurposing were also screened, such as DrugRepurposingHub [66] . In other cases, in-house databases were used. Many studies were made available as non-peer-reviewed preprints; in this review, we will not take them into account, judging them not sufficiently reliable. Of those published in a peer-reviewed form, we noticed that several papers were subjected to an accelerated peer-review process (less than 15 days) ( Table 2) , therefore these results must be considered with caution. The results of most structure-based studies on drug repurposing against COVID-19 pandemic are summarized in Tables 3, 4 and 5. This list does not pretend to be exhaustive, given the speed by which new articles on these subjects are published. Most studies were focused to predict the ability of known drugs to bind SARS-CoV-2 Mpro . However, little agreement is present among the potential candidates identified by these different studies. A possible reason could be the diversity of the selected starting databases and of the algorithms used in docking and virtual screening. Furthermore, a study on the structural properties of Mpro [96] found deep differences in the shape and size of the active sites of this protease with respect to SARS-CoV protease, suggesting that the repurposing of SARS drugs for COVID-19 may be ineffective. Most of the hits discovered in these studies belong to few classes of drugs: antiretrovirals, antineoplastic, antimalarial, immunomodulators, nucleotide inhibitors, protease inhibitors, ri-bonucleoside inhibitors and steroid hormones. Another main target for drug-repurposing studies is spike protein (Supplementary Figure 2) , which confers to the virus its "crown" appearance and facilitates the binding with host ACE2 receptor, thus allowing the virus to enter the host cell [23, 24, 97] . Several studies were conducted targeting this protein [98] [99] [100] [101] [102] [103] . In general, this protein has been proved a more difficult target than Mpro, and few drugs have been found. The article by Feng and coworkers [102] , focused on the search for ligands of spike into a database of FDA-approved drugs, is the only one that provided an in vitro validation of the results, showing that eltrombopag, a non-peptide thrombopoietin receptor agonist, has a Kd for human ACE2 extracellular domain of 8.275×10 −7 M and can also bind the S2 domain of spike protein with a Kd in the micromolar range. Therefore, this drug is potentially able to impair viral entrance in host cells. Two articles [104, 105] performed virtual screening on the homology model of the structure of human TMPRSS2, which facilitates cell entry of SARS-CoV-2 through the spike protein, and predicted benzquercin as the most promising hit for this protease. Studies for drugs impairing other macromolecular targets of SARS-CoV-2 are more scarce. RdRp was the focus of few studies [106] [107] [108] [109] . In some cases, the authors reported that antivirals targeting RdRp of other viruses (HCV, MERS and SARS) such as sofosbuvir and remdesivir could bind and stop the activity of this protein. A recent clinical trial did not confirm the activity of remdesivir against SARS-CoV-2 [110] but other studies suggested that this drug can shorten the time to recovery in some patients [111] . On this basis, FDA issued an emergency use authorization for remdesivir for the treatment of COVID-19 patients hospitalized with severe disease. PLpro (Supplementary Figure 3) was the molecular target of a study [112] to evaluate the repositioning of FDAapproved antivirals, antibiotics, anthelmintics, antioxidants and cell protectives. Another study [113] predicted that zidovudine, an anti-HIV agent, could be able to bind to nucleocapsid protein (Supplementary Figure 4) . Another article [114] targeted three differential traits of the intermolecular interactions of the RNA cap 2'-O-methyltransferase nsp16/nsp10 protein complex (Supplementary Figure 5) , i.e. the (nsp10-stabilized) SAM-binding pocket of nsp16, the (nsp10-extended) RNA-binding groove of nsp16 and the unique nsp16/nsp10 interaction interface required by nsp16 to execute its enzymatic activity. Also, another study [115] applied structure-based drug repurposing to nsp16. Multitarget studies were also performed. Starting from a strategy already developed against Ebola and Zika viruses, and considering compounds with in vitro activity against SARS and MERS, drug repurposing has been applied on the structures of spike+ACE2 interface and Mpro [116] . Other studies focused on the structures of the following targets: Mpro and TMPRSS2 [117] ; RdRp, Mpro and helicase [118] ; and Mpro, spike and PLpro [119] . Other authors [120] focused the study on the prediction of the interaction of saikosaponins (components of traditional Chinese medicine) with spike and nsp15. In two articles, the authors modelled all the proteins of SARS-CoV-2 and performed screening against all these targets. The 1st article compared the structures of known ligands of the templates used to model SARS-CoV-2 proteins to a dataset of drugs and active metabolites [121] , whereas the 2nd article used these models to perform docking of a selected group of FDA-approved antiviral compounds and a library of natural compounds [122] . In their study, Mahdian and coworkers modelled five target proteins of SARS-CoV-2 (Mpro, PLpro, cleavage site, HR1 and RBD in Spike protein) and screened FDA-approved drugs against them [123] . Another multitarget study focused on quinolin-based inhibitors [124] . Most of these structure-based repurposing studies included in the library of compounds tested also treatments that gained attention not only to the scientific community. In particular, chloroquine and hydroxychloroquine, two old antimalarial drugs [125] , and lopinavir and ritonavir, two anti-AIDS drug introduced in the therapy against SARS-CoV-2 [126] were predicted to bind several SARS-CoV-2 proteins. However, no benefit was observed with lopinavir-ritonavir treatment with respect to standard care in a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection [127] , and the utility of chloroquine/hydroxychloroquine in the treatment of COVID-19 is still questioned [128, 129] . An additional contribution to the structure-based approach of drug repurposing was given by researchers that developed freely accessible Web servers to predict targets and for multitarget-and multi-site-based virtual screening. One example is D3Targets-2019-nCoV (https://www.d3pharma.com/D3Targets-2019-nCoV/index.php), which contains 20 viral proteins and 22 human proteins involved in virus infection, replication and release, with 69 different conformations and 557 potential ligand-binding pockets [130] . Other Web servers are available but not (yet) associated to peer-reviewed publications. AI researchers are very active to fight COVID-19 effects, but few papers are concerning drug repurposing. In addition, although some of them have been written and publicly available, we found only few papers accepted for publication and online available on a journal, also if subjected to an accelerated peer-review process. In [131] authors proposed a deep learning approach for searching marketed drugs potentially with antiviral activities against coronaviruses. The system was proposed to quickly screen a large number of compounds with assigned learning datasets to find those with potential activities inhibiting SARS-CoV-2. An in vitro cell model for feline coronavirus replication was set up to evaluate the AI-identified drugs for antiviral activity verification. The systems was integrated with a feedback from antiviral activities by a cell-based FIP virus replication assay and the retrained AI model was established to screen further and again verified by the FIP virus replication assay. In [132] authors used a previously trained deep learning-based drug-target interaction prediction model, called Molecule Transformer-Drug Target Interaction (MT-DTI) [133] to identify commercially available antiviral drugs that could potentially disrupt SARS-CoV-2 viral components, such as proteinase, RNA-dependent RNA polymerase and/or helicase. Since the model utilizes simplified molecular-input line-entry system (SMILES) strings and amino acid (AA) sequences, which are 1D string inputs, it is possible to quickly apply target proteins that do not have experimentally confirmed 3D crystal structures, such as viral proteins of SARS-CoV-2. To train the model, the Drug Target Common (DTC) database [134] and BindingDB [135] database were manually curated and combined. After the MT-DTI prediction, the raw prediction results were screened for antiviral drugs that are FDA approved and target viral proteins. To confirm the performance of MT-DTI at least in silico, authors compared the binding affinities of 3,410 FDA-approved drugs predicted by MT-DTI to those estimated by AutoDock Vina (a widely used 3D structurebased docking algorithm) [136] . The problem here is that the two models did not obtained exactly comparable results and then because a ground truth or in vivo experiments are necessary to confirm in-vitro hypotheses. On the other hand, the AI community is giving additional contributions to fighting COVID-19 by developing freely accessible Web servers and resources, as in the case of the CLAIRE Innovation Network, composed of 381 laboratories and institutions working in Europe in the area of AI (https://covid19.claire-ai.org/). In this context, also drug repositioning is one of the research topics by making available both data and computing facilities to interested researchers. Drug repositioning is a field of drug research whose importance has been increasing in the past years, due to several advantages, such as the possibility to shorten the clinical trials, the extension of the life of an old drug by finding a new therapeutic target and the discovery of often-unknown relationships among apparently distant diseases. The urgency to find drugs to face COVID-19 pandemic has tremendously pushed this kind of research in the past months. Computational approaches has played and still play a major role to search weapons effective against SARS-CoV-2 virus among the arsenal of drugs available today, but to date, the results do not appear to live up to expectations. Judging by the literature, a major role in this race against time was played by structural bioinformatics, whose contribution was made possible also by the unprecedented speed with which the structures of the most important viral proteins were made available. However, many results of these studies appear not fully convincing. Very few studies on the same target converge on the same drugs, very few give an unquestionable evidence of an effect and almost none gives an experimental validation. Furthermore, many studies predict the effectiveness of discussed drugs that failed to demonstrate their efficacy in clinical trials. We noticed that speed is the common feature of these studies. A proverb says: "haste makes waste", and what is true for popular wisdom is doubly true for scientific research, which needs time to carefully design a good experiment (irrespective if in wet laboratory or in silico), time to carefully perform it and, especially, time to carefully understand the results. Moreover, publications have also often been evaluated hastily, as it has been well explained in a work published by Palayew and coworkers [137] . We agree with their concerns and with their comment: "Although the nature of this emergency warrants accelerated publishing, measures are required to safeguard the integrity of scientific evidence". It is true that the world is struggling desperately to find a drug against SARS-CoV-2 as soon as possible, but science must resist the temptation to jump the gun and pursue the goal with the same rigor as ever. On the other hand, AI-based and network-based approaches probably made a smaller contribution to the field of drug repurposing than would have been expected. Possibly, the reason is that these methods are based on knowledge, and at present we do not have a sufficient critical mass of knowledge about an organism whose existence was unknown until less than a year ago. This demonstrates the importance of basic research, often underestimated, as an indispensable substrate for the growth of knowledge essential for the development of research applied to biomedicine. Despite everything, the computationally based drug-repositioning approaches applied to COVID-19 have made it possible to highlight some drugs that would be worth testing into COVID-19 therapy, most of which are in the same therapeutic area of their current registered use, therefore their probability of success is high [14] . We are confident that they will be able to make an even more important contribution to win this battle against COVID-19 in the future. • Drug repurposing is an approach that has been proven effective to find drug against diseases. • The urgency of a pandemic condition may benefit of the drug-repurposing approach, thanks to the already available approvals for using in humans. • Critical aspects in the application of drug repurposing are the availability of data suitable to apply AI methods and the time needed for a careful evaluation of results before approving for publication. Supplementary data are available online at https://academic. oup.com/bib. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines Computational and experimental advances in drug repositioning for accelerated therapeutic stratification Drug repurposing by integrated literature mining and drug-gene-disease triangulation An update on Drug Repurposing: Re-written saga of the drugs fate Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics Drug repositioning: concept, classification, methodology, and importance in rare/orphans and neglected diseases In vitro screening for drug repositioning Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics Exploration of databases and methods supporting drug repurposing: a comprehensive survey Review of drug repositioning approaches and resources Transcriptional data: a new gateway to drug repositioning? In silico studies on therapeutic agents for COVID-19: Drug repurposing approach Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2-O-ribose methyltransferase Renovation as innovation: is repurposing the future of drug discovery research? A survey of current trends in computational drug repositioning Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2 A review of computational drug repurposing Computational functional genomics-based approaches in analgesic drug discovery and repurposing Review of drug repositioning approaches and resources A bibliometric review of drug repurposing Combating devastating COVID-19 by drug repurposing Coronavirus disease 2019 (COVID-19) pandemic and pregnancy SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven prote-ase inhibitor Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach Master Regulator Analysis of the SARS-CoV-2/Human Interactome A SARS-CoV-2 protein interaction map reveals targets for drug repurposing The epidemiology and pathogenesis of corona-virus disease (COVID-19) outbreak Virology, epidemiology, pathogenesis, and control of COVID-19 Traditional chinese medicine-based network pharmacology could lead to new multicompound drug discovery Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model Network-based drug-target interaction prediction with probabilistic soft logic Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories Network-based inference methods for drug repositioning Pathway-based drug repositioning using causal inference Construction of drug network based on side effects and its application for drug repositioning A review of SARS-CoV-2 and the ongoing clinical trials Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019 COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing Protein complex prediction with RNSC RRW: repeated random walks on genome-scale protein networks for local cluster discovery Identification of protein complexes by integrating multiple alignment of protein interaction networks Detecting overlapping protein complexes in protein-protein interaction networks An automated method for finding molecular complexes in large protein interaction networks Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm Associating Genes and Protein Complexes with Disease via Network Propagation DrugNet: networkbased drug-disease prioritization by integrating heterogeneous data Molecular docking: shifting paradigms in drug discovery Molecular docking: a structure-based approach for drug repurposing Repurposing Techniques and Methodologies Homology models in docking and highthroughput docking Announcing the worldwide Protein Data Bank Combining docking and molecular dy-namic simulations in drug design ZINC 15-ligand discovery for everyone PubChem 2019 update: improved access to chemical data DrugBank 5.0: a major update to the DrugBank database for 2018 Data sets representative of the structures and experimental properties of FDA-approved drugs SuperDRUG2: a one stop resource for approved/marketed drugs ChEMBL: towards direct deposition of bioassay data KEGG for integration and interpretation of large-scale molecular data sets MTiOpenScreen: a web server for structure-based virtual screening The Drug Repurposing Hub: a next-generation drug library and information resource Moroccan medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target Computational insights into tetracyclines as inhibitors against SARS-CoV-2 Mpro via combinatorial molecular simulation calculations An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition Potential inhibitors of corona-virus 3-chymotrypsin-like protease (3CLpro): an in silico screening of alkaloids and terpenoids from African medicinal plants Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19 A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2 Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors Virtual screening and repurposing of FDA ap-proved drugs against COVID-19 main protease Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CLpro) In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drugrepurposing Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication Molecular docking and simulation studies on SARS-CoV-2 Mpro reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19 Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19 Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms High throughput virtual screening to discover inhibitors of the main protease of the coronavirus SARS-CoV-2 Peptide-like and small-molecule inhibitors against Covid-19 Drug repurposing for candidate SARS-CoV-2 main protease inhibitors by a novel in silico method Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study Structural and evolutionary analysis indicate that the SARS-CoV-2 Mpro is a challenging target for small-molecule inhibitor design Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of com-bating Covid-19 infectivity Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloro-quine against SARS-CoV-2 infection Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein In silico screening of potential spike gly-coprotein inhibitors of SARS-CoV-2 with drug repurposing strategy Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target Structure-based drug repo-sitioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a drug repurposing study Evaluating the potential of different inhibitors on RNA-dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2: a molecular modeling approach Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial COVID-19 therapeutic options under investigation Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2 Potential drugs targeting early innate immune evasion of SARS-coronavirus 2 via 2-Omethylation of viral RNA Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study Déjà vu: Stimulating open drug discovery for SARS-CoV-2 Drug repurposing for corona-virus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods Drug repurposing using computational methods to identify therapeutic options for COVID-19 Quinolinesbased SARS-CoV-2 3CLpro and RdRp inhibitors and Spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: an in silico analysis Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro COVID-19 treatment: close to a Cure? A rapid review of pharmacotherapies for the novel coronavirus A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19 Chloroquine and COVID-19 -a potential game changer? Role for antimalarials in the management of COVID-19 D3Targets-2019-nCoV: a webserver for pre-dicting drug targets and for multi-target and multi-site based virtual screening against COVID-19 Artificial intelligence approach fighting COVID-19 with repurposing drugs Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model Self-attention based molecule representation for predicting drug-target interaction Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction profiles BindingDB: a web-accessible database of exper-imentally determined protein-ligand binding affinities AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading Pandemic publishing poses a new COVID-19 challenge The authors declare to have not any conf lict of interest.